GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., No. 18-1976 (Fed. Cir. Oct. 2, 2020)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

GlaxoSmithKline LLC and SmithKline Beecham (Cork) Ltd. (collectively, “ GSK”) charge d Teva Pharmaceuticals USA, Inc. with infringement of GSK’s Reissue Patent No. RE40,000 (“the ’000 patent”). Trial was GLAXOSMITHKLINE LLC v. TEVA PHARMACEUTICALS USA, INC. 3 held in the United States District Court for the District of Delaware; the jury found the patent valid and infringed , and assessed damages. The jury also found that the infringement was willful.